Stig BRORSON 1, Joanne ELLIOTT 2, Theis THILLEMANN 3, Patricia ALUKO 4, and Helen HANDOLL 2,5
1 Centre for Evidence-Based Orthopaedics, Zealand University Hospital and Department of Clinical Medicine University of Copenhagen, Denmark; 2 Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, UK; 3 Department of Orthopaedics, Shoulder and Elbow Unit, Aarhus University Hospital, Aarhus N, Denmark; 4 National Institute for Health Research (NIHR) Innovation Observatory, Newcastle University, Newcastle Upon Tyne, UK; 5 Department of Orthopaedics and Trauma, The University of Edinburgh, Edinburgh, UK
Citation: Acta Orthopaedica 2022; 93: 610–612. DOI https://doi.org/10.2340/17453674.2022.3495.
Copyright: © 2022 The Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
Submitted: 2022-06-08. Accepted: 2022-06-21. Published: 2022-07-04.
Correspondence: sbror@regionsjaelland.dk
This article is based on a Cochrane Review published in the Cochrane Database of Systematic Reviews (CDSR) 2022, Issue 6, DOI: 10.1002/14651858.CD000434.pub5. (see www.cochranelibrary.com for information).
The authors would like to acknowledge the support by the Cochrane Bone, Joint and Muscle Trauma Review Group.
Fractures of the proximal humerus are common injuries, especially in older people. Patients are managed on a daily basis in most emergency departments and orthopedic clinics. Definitive treatment is either non-surgical or surgical where options include open reduction and internal fixation with locking plates, intramedullary nailing, hemiarthroplasty (HA) and, most recently, reverse total shoulder arthroplasty (RTSA) (1). Preferred treatment approaches, including the use of surgery for displaced fractures, vary geographically and between hospitals.
The evidence base for treatment of proximal humeral fractures has expanded substantially within the last decade and several high-quality randomized trials are now available. To assist clinical decision-makers and help inform patients, our Cochrane review aimed to provide critical summaries of the available best quality evidence for treatment options.
We present the key messages from an enlarged and updated Cochrane review (2) based on 47 randomized trials with 3,179 participants.
For a systematic review and meta-analysis we included the randomized trials identified in our search of multiple databases up to September 2020. We updated our search in November 2021, and assessed the suitability of newly identified trials for inclusion: no newly published trials were available or otherwise suitable for immediate inclusion for our 4 main comparisons. Pairs of review authors independently selected studies, assessed risk of bias, and extracted data. We pooled data where appropriate and used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach for assessing the certainty of evidence for each outcome (see Table 1 for interpretation). The review does not cover 2-part tuberosity fractures, fracture-dislocations, articular surface fractures and fractures in young people.
Of the 47 included trials, 12 evaluated non-surgical treatments, 10 compared surgical with non-surgical treatments, 23 compared 2 methods of surgery, and 2 tested timing of mobilization after surgery. Only 6 of the 26 comparisons presented in the review were tested by 2 or more trials. 4 of the 6 multi-trial comparisons were prioritized a priori for presentation. These are summarized below.
This key comparison was based on 10 trials with 717, predominantly older (aged 60 years or over), participants suffering a displaced 2-, 3-, or 4-part fracture involving the humeral neck. The findings for 3 key outcomes are shown in Table 2. We found high-certainty evidence of no clinically important difference between surgical and non-surgical treatment in patient-reported shoulder function at 1 year (Figure 1) or at 2 years (423 participants). We found moderate-certainty evidence of no clinically important difference in patient-reported shoulder function at 6 months (347 participants). We found high-certainty evidence of no clinically important difference in quality of life at 1 year. We found low-certainty evidence of a higher risk of additional surgery in the surgery group (Figure 2). Surgical treatments in the 10 trials included locking plates, HA, or RTSA.
Patients: older patients with displaced (Neer) proximal humeral fractures treated at hospital (10 trials, 717 participants) Intervention: surgical treatment: usually locking plate or hemiarthroplasty; reverse shoulder arthroplasty used in 1 trial Comparison: non-surgical treatment: sling ‘immobilisation’; closed reduction in 2 trials Outcome: functional score and quality of life at 1 year, additional surgery at 2 years |
||||||
Outcomes | Illustrative comparative risks a (95% CI) | Relative effect (95% CI) | No. of participants (studies) | Certainty of the evidence (GRADE) | Comments | |
Assumed risk Non-surgical treatment | Corresponding risk Surgical treatment | |||||
Functional scores a (higher = better outcome) Follow-up: 1 year | The overall mean difference in function was 0.10 SD higher (0.07 lower to 0.27 higher) | SMD 0.10 b (–0.07 to 0.27) | 552 participants (7 studies) | ⊕⊕⊕⊕ High | All estimates of between-group differences were smaller than the predefined MCID for individual scores | |
Quality of life: EQ-5D (1: best quality of life) Follow-up: 1 year | Mean score ranged from 0.65 to 0.90 | The mean EQ-5D score in the surgery groups was 0.01 higher (0.02 lower to 0.04 higher) | MD 0.01 (–0.02 to 0.04) | 502 participants (6 studies) | ⊕⊕⊕⊕ High | The MCID of 0.12 was outside the 95% CI at this time period. |
Additional surgery (re-operation or secondary surgery) Follow-up: up to 2 years | 35 per 1,000 | 73 per 1,000 (43–129) | RR 2.06 (1.21–3.51) | 667 participants (9 studies) | ⊕⊕⊕⊕ Low | Additional surgery was reported for 54 participants in total. |
CI: confidence interval; EQ-5D: European Quality of Life-5 Dimensions; MCID: minimal clinically important difference; MD: mean difference; RR: risk ratio; SMD: standardised mean difference a American Shoulder and Elbow Surgeons score (ASES; 1 trial), Disability of the Arm, Shoulder and Hand questionnaire (DASH; 4 trials), Oxford Shoulder Score (OSS; 1 trial); Simple Shoulder Test (SST; 1 trial) b SMD 0.2: small difference, 0.5: moderate difference, 0.8 large difference |
Figure 1. Surgical versus non-surgical treatment: functional scores at 12 months
Figure 2. Surgical versus non-surgical treatment: additional surgery (re-operation or secondary surgery)
5 trials compared early versus delayed mobilization (350 participants). Very-low certainty evidence from single study trials means that we are uncertain in the finding of better shoulder function at 1 year in the early mobilization group (82 participants), or in the findings of no or little between-group difference in function at 3 months (50 participants) or at 2 years (74 participants). We found very low-certainty evidence of no important between-group difference in quality of life at 1 year. 5 serious shoulder complications, spread between the 2 groups, were reported.
4 trials compared these 2 methods (270 participants, mainly 2-part fractures). We found low-certainty evidence of no clinically important between-group difference in shoulder function at 1 year (227 participants), at 6 months (174 participants), or at 2 years (101 participants). We found very low-certainty evidence of no between-group difference in quality of life (53 participants), and of little between-group differences in adverse events (250 participants) and additional surgery (193 participants).
There was very low-certainty evidence from 2 trials (161 participants, 3- or 4-part fractures, some fracture-dislocations) of no or minimal between-group differences in self-reported shoulder function or quality of life at 1 or at a minimum of 2 years’ follow-up. There was very low-certainty evidence of a lower risk of complications after RTSA (160 participants). 10 people (6 %) underwent reoperation; all 8 cases in the HA group received an RTSA (very low-certainty evidence).